Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Walgreens’ breakup sets stage for retail pharmacy focus

The news: Walgreens Boots Alliance will be spun out into five standalone companies following its official sale to private equity firm Sycamore Partners.

The five separate entities will be:

  • Walgreens
  • Shields Health Solutions (specialty pharmacy)
  • CareCentrix (home health)
  • VillageMD (primary care)
  • The Boots Group (Walgreens’ international health and beauty retail chain)

Zooming in: Walgreens appointed Mike Motz as its next CEO. Motz was previously CEO of Staples US Retail, a Sycamore portfolio company. He also served as president of Shoppers Drug Mart, a pharmacy chain in Canada.

Why it matters: Sycamore will likely make retail pharmacy a core priority, despite ongoing headwinds in the sector.

Walgreens’ pharmacy business is Sycamore’s most successful entity ($100B in 2024 prescription drug revenues) in the biggest market it operates in. Motz is a retail veteran with pharmacy leadership experience, and his hiring signals that Sycamore is keen on getting Walgreens to deliver a better pharmacy customer experience while improving front–of-store drugstore sales.

Additionally, the new organizational structure indicates that Sycamore will shop around some of its non-core assets since there are more operational complexities with spinning off parts of an integrated company. VillageMD is the likeliest deal candidate due to its poor financial performance, even if a sale will only return a fraction of the $6 billion-plus Walgreens invested in the primary care provider.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account